Lam Research (NASDAQ:LRCX - Get Free Report) had its price target boosted by Rothschild & Co Redburn from $115.00 to $140.00 in a research note issued on Wednesday,MarketScreener reports. The firm presently has a "buy" rating on the semiconductor company's stock. Rothschild & Co Redburn's price target points to a potential upside of 4.56% from the stock's current price.
Several other equities research analysts also recently issued reports on LRCX. Erste Group Bank assumed coverage on shares of Lam Research in a research note on Thursday, August 14th. They issued a "buy" rating on the stock. TD Cowen boosted their price target on Lam Research from $100.00 to $125.00 and gave the company a "buy" rating in a research note on Thursday, July 31st. Morgan Stanley set a $125.00 price objective on Lam Research and gave the stock an "equal weight" rating in a research report on Monday, September 22nd. Raymond James Financial boosted their price objective on Lam Research from $90.00 to $110.00 and gave the company an "outperform" rating in a research report on Thursday, July 31st. Finally, B. Riley lifted their price target on shares of Lam Research from $130.00 to $160.00 and gave the stock a "buy" rating in a research note on Wednesday, September 24th. Twenty-two investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, Lam Research presently has a consensus rating of "Moderate Buy" and a consensus price target of $117.72.
View Our Latest Report on LRCX
Lam Research Stock Up 2.1%
Shares of LRCX stock opened at $133.90 on Wednesday. The company has a market capitalization of $168.85 billion, a price-to-earnings ratio of 32.19, a PEG ratio of 1.65 and a beta of 1.76. The company has a debt-to-equity ratio of 0.38, a quick ratio of 1.55 and a current ratio of 2.21. The stock's 50 day simple moving average is $107.60 and its 200 day simple moving average is $90.97. Lam Research has a twelve month low of $56.32 and a twelve month high of $134.21.
Lam Research (NASDAQ:LRCX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The semiconductor company reported $1.33 EPS for the quarter, beating the consensus estimate of $1.21 by $0.12. Lam Research had a return on equity of 58.17% and a net margin of 29.07%.The company had revenue of $5.17 billion for the quarter, compared to the consensus estimate of $4.99 billion. During the same quarter last year, the company posted $1.03 earnings per share. The company's revenue for the quarter was up 33.6% compared to the same quarter last year. Lam Research has set its Q1 2026 guidance at 1.100-1.300 EPS. As a group, research analysts predict that Lam Research will post 3.71 EPS for the current year.
Hedge Funds Weigh In On Lam Research
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Smallwood Wealth Investment Management LLC bought a new stake in shares of Lam Research in the 1st quarter valued at about $26,000. IMG Wealth Management Inc. bought a new stake in shares of Lam Research in the second quarter worth about $26,000. Howard Hughes Medical Institute acquired a new stake in Lam Research during the 2nd quarter worth approximately $27,000. Strategic Wealth Investment Group LLC bought a new position in Lam Research during the 2nd quarter worth about $29,000. Finally, Delos Wealth Advisors LLC bought a new stake in shares of Lam Research in the second quarter valued at about $30,000. 84.61% of the stock is owned by institutional investors.
Lam Research Company Profile
(
Get Free Report)
Lam Research Corporation designs, manufactures, markets, refurbishes, and services semiconductor processing equipment used in the fabrication of integrated circuits. The company offers ALTUS systems to deposit conformal films for tungsten metallization applications; SABRE electrochemical deposition products for copper interconnect transition that offers copper damascene manufacturing; SOLA ultraviolet thermal processing products for film treatments; and VECTOR plasma-enhanced CVD ALD products.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Lam Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lam Research wasn't on the list.
While Lam Research currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.